Bafna Pharmaceuticals (NSE:BAFNAPH) EV-to-FCF: (As of Jun. 29, 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
60 GF Score
Price ₹194.68
GF Value ₹91.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bafna Pharmaceuticals's Enterprise Value is ₹5,033 Mil. Bafna Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Bafna Pharmaceuticals's EV-to-FCF for today is .

The historical rank and industry rank for Bafna Pharmaceuticals's EV-to-FCF or its related term are showing as below:

NSE:BAFNAPH' s EV-to-FCF Range Over the Past 10 Years
Min: -52.8   Med: 0   Max: 0
Current: -52.8

NSE:BAFNAPH's EV-to-FCF is ranked worse than
100% of 559 companies
in the Drug Manufacturers industry
Industry Median: 20.02 vs NSE:BAFNAPH: -52.80

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-29), Bafna Pharmaceuticals's stock price is ₹194.68. Bafna Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.690. Therefore, Bafna Pharmaceuticals's PE Ratio (TTM) for today is 41.51.


Bafna Pharmaceuticals  (NSE:BAFNAPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Bafna Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=194.68/4.690
=41.51

Bafna Pharmaceuticals's share price for today is ₹194.68.
Bafna Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.690.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bafna Pharmaceuticals EV-to-FCF Related Terms


Bafna Pharmaceuticals EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals EV-to-FCF Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 142.41 -64.49 -32.11 732.03 -31.58

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 732.03 0.00 0.00 0.00 -31.58

NSE:BAFNAPH vs ZTS, UTHR: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's EV-to-FCF falls into.


NSE:BAFNAPH
60GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals EV-to-FCF Calculation

Bafna Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=5032.745/0
=

Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹194.68 is trading 112.1% above its estimated GF Value™ of ₹91.79. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • EV-to-FCF:
  • GF Value™: ₹91.79 vs. price of ₹194.68 (112.1% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score

Get the complete analysis for NSE:BAFNAPH

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.68
Price
₹91.79
GF Value